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Background
High-dose melphalan (200 mg/m
2) with autologous stem cell transplantation (ASCT) is 
the standard treatment for young patients with multiple myeloma (MM). However, the 
response rates after ASCT are often unsatisfactory. We performed a pilot study by using 
bortezomib-melphalan as conditioning regimen for ASCT in Korean patients with MM.
Methods
The conditioning regimen consisted of administration of intravenous infusion of bortezo-
mib 1.0 mg/m
2 on days -4 and -1 and melphalan 50 mg/m
2 (day -4) and 150 mg/m
2 (day 
-1). In this study, we enrolled 6 newly diagnosed patients and 2 patients with relapse.
Results
The disease status of the 6 newly diagnosed patients at ASCT was as follows: 1 complete 
remission (CR), 1 very good partial remission (VGPR), and 4 partial remissions (PRs). The 
disease status of the 2 relapsed patients at ASCT was PR. All patients except 1 showed 
adequate hematologic recovery after ASCT. The median time for the absolute neutrophil 
counts to increase over 500/mm
3 was 13 days (range, 10-19 days). Six patients with VGPR 
or PR at the time of transplantation showed an improvement in response to CR after ASCT. 
The patients were followed up without any maintenance treatment after ASCT except 1 
patient who died during ASCT. During the follow-up period, CR was maintained in 3 newly 
diagnosed patients, but the other 4 patients, including 2 newly diagnosed patients, 
relapsed.
Conclusion
Conditioning regimen consisting of bortezomib and melphalan may be effective for ASCT 
in MM; however, the feasibility of this regimen should be further evaluated in large study 
populations.
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INTRODUCTION
  Intravenous administration of high-dose of melphalan fol-
lowed by autologous stem cell transplantation (ASCT) in-
duces higher response rates and improved treatment out-
comes compared to that with standard dose melphalan, as 
reported in previous randomized trials [1, 2]. High-dose mel-
phalan (200 mg/m
2) has been widely used in patients with 
multiple myeloma (MM) and is known as the most effective 
available conditioning regimen for MM [3]. However, relapse 
is still common, and the response rates after ASCT are often 
unsatisfactory. A high-dose conditioning regimen mainly 
contributes to the efficacy of ASCT by the cytoreduction 
effect, and thus, development of a more effective condition-
ing regimen may help in improving the outcome of ASCT. 
However, convincing evidence indicating that any con-
ditioning regimen is superior to high-dose melphalan (200 
mg/m
2) without additional toxicities is not available [3-6].
  Bortezomib (VELCADE; Millennium Pharmaceuticals, 
Inc., Cambridge, MA, USA and Johnson & Johnson LLC, 
Raritan, NJ, USA) is the first proteasome inhibitor approved 
for MM therapy. The efficacy of bortezomib has been shown 
in previous clinical trials with a large study population [7-9]. 
In addition, bortezomib has shown synergistic effects with 
chemotherapeutic agents in a preclinical model [7, 8, 10]. Korean J Hematol 2010;45:183-7.
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Fig. 1. Schematic diagram of the bortezomib and melphalan condi-
tioning regimen. B, bortezomib 1 mg/m
2; M50, melphalan 50 mg/m
2; 
M150, melphalan 150 mg/m
2; PBSC, peripheral blood stem cell.
The efficacy of administration of bortezomib and melphalan 
has suggested synergistic effects between these 2 drugs [11, 
12]. Thus, the combination of bortezomib with high-dose 
melphalan as conditioning regimen may present a promising 
approach to improve response rates in MM patients after 
ASCT. A group from the University of Arkansas suggested 
the possibility of a bortezomib-melphalan conditioning regi-
men in an abstract presented in the annual meeting of 
American Society of Hematology 2004 (Hollmig K, et al. 
Blood 2004; Abstract #929). Therefore, we performed a pilot 
study in which we combined bortezomib and high-dose mel-
phalan as a conditioning regimen for ASCT in Korean patients 
with MM.
MATERIALS AND METHODS
  Patients under 65 years of age with symptomatic MM 
were included in this study provided that they were eligible 
for high-dose therapy (HDT) and had a non-progressive dis-
ease at the time of ASCT. The exclusion criteria were: a 
serum creatinine level of ≥2.5 mg/dL at the time of HDT; 
liver insufficiency, e.g., a total serum bilirubin level of 2.0 
mg/dL, serum aspartate/alanine aminotransferase levels or 
alkaline phosphatases level more than 3.0×the upper limit 
of normal; a left ventricular ejection fraction of ≤50%, and 
a pulmonary diffusion capacity of ≤50% of predicted; a 
grade 3 or worse peripheral neuropathy, significant comorbid 
disease that would preclude ASCT; and a history of any 
other malignant disease within the past 5 years, except cura-
tively treated non-melanoma skin cancer or in situ carcinoma 
of cervix uteri.
  The conditioning regimen was designed according to the 
previous report (Hollmig K, et al. Blood 2004; Abstract #929), 
and it was as follows. On day -4, bortezomib (1.0 mg/m
2) 
and melphalan (50 mg/m
2) were infused intravenously (IV). 
Bortezomib (1.0 mg/m
2) and melphalan (150 mg/m
2) were 
infused IV on day-1, followed by stem cell support on day 
0 (Fig. 1). All patients received standard supportive care 
measures, including growth factor support, blood trans-
fusions, and prophylactic or therapeutic antibiotics. Prophy-
lactic antibiotics, including acyclovir (400 mg q 12 h) were 
used from day -5. We evaluated the response status at 6 
weeks after ASCT according to the International Myeloma 
Working Group Criteria. Because serum free light chain 
assay was not available in our institute during this study, 
stringent complete remission (sCR) could not be evaluated. 
Toxicities were graded according to the National Cancer 
Institute Common Toxicity Criteria of Adverse Events, ver-
sion 3.0. Overall survival (OS) was measured from the date 
of ASCT to the date of death or last follow-up visit. 
Progression-free survival (PFS) was defined as the time from 
ASCT to disease progression or death. Patients were followed 
up to December 2009. The institutional review board of 
Korea University Medical Center approved this study.
RESULTS
  Between April 2005 and January 2008, 8 patients received 
bortezomib and high-dose melphalan conditioning prior to 
ASCT. Six newly diagnosed patients (No. 1-6) received 4-6 
cycles of vincristine, adriamycin, and dexamethasone (VAD) 
combination chemotherapy as induction treatment. The dis-
ease statuses of these 6 patients at the time of ASCT were 
1 complete remission (CR), 1 very good partial remission 
(VGPR), and 4 partial remissions (PR). Two relapsed patients 
received 2 kinds of treatment (VAD and thalidomide/dex-
amethasone) before ASCT, and their disease status was PR 
(Table 1). Peripheral blood stem cells were mobilized using 
granulocyte colony-stimulatory factor (G-CSF) infusion 
(filgrastim, 10 μg/kg IV for 3 days) in 4 patients, cyclo-
phosphamide mobilization chemotherapy plus G-CSF in-
fusion was performed in the remaining 4 patients. The me-
dian number of collected CD34+ cells was 4.5×10
6/kg (range, 
3.5-9.0×10
6/kg). The median time of the absolute neutrophil 
count to rise over 500/mm
3 was 13 days (range, 10-19 days), 
and the median time of the platelet count to rise over 
20,000/mm
3 was 17 days (range, 14-20 days). Seven patients 
experienced an episode of febrile neutropenia. Although all 
of these patients recovered after empirical antibiotics ther-
apy, 1 patient (No. 6) developed respiratory distress at around 
day +7. This patient died due to right upper lobar pneumonia 
on day +11. The most frequently reported non-hematologic 
toxicities, except fever, were mucosites, and these toxicities 
were manageable (Table 2). It should be noted that peripheral 
neuropathy was present at the time of ASCT in 2 patients 
and did not worsen after conditioning. Non-hematologic 
toxicities, including peripheral neuropathy, were unremar-
kable. Six patients with VGPR or PR at the time of trans-
plantation showed an improvement in response to CR after 
ASCT (Table 1). The patients were followed up after ASCT 
without any maintenance treatment. The median follow-up 
duration was 27.3 months (range, 4.0-51.7 months) and CR 
was maintained in 3 newly diagnosed patients, but the other 
4 patients, including 2 newly diagnosed patients, relapsed 
(Table 1). Korean J Hematol 2010;45:183-7.
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Table 1. Summary of patients.
No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 8
Gender Male Male Female Female Female Male Male Male
Age 
a) 65 52 35 39 37 58 41 38
ECOG performance status
a) 2 2 2303 3 2
DS stage
b) II A II A II A III A IIA IIIA IIIB IIIA
ISS stage 
c) III II I II II II III II
Extramedullary involvement Lumbosacral 
spines
Thoracic 
spines
Lumbar 
spines and 
spleen
Thoracic 
spines and 
both ribs
Thoracic 
spines
Whole 
spines
Kidney and 
lumbar 
spines
Lumbosacral 
spines
Serum beta-2 microglobulin (mg/L) 8.68 3.8 2.09 3.64 2.46 5.47 17.08 3.53
Serum albumin (g/dL) 4.3 5.5 4.5 4.2 3.3 2.4 4.6 3.5
Serum creatinine (mg/dL) 1.1 1.2 0.7 0.8 0.9 0.9 6.4 0.9
Type Lamda 
light chain
Non-secretory 
type
IgG, kappa IgD, lamda IgG lambda IgG, kappa IgG, kappa  Lamda light 
chain
M-protein 5.1 g/24 h
 urine
Not 
detectable
1.36 g/dL 1.30 g/dL 5.21 g/dL 5.56 g/dL 7.8 g/dL 7.8 g/24 hr
 urine
Bone marrow plasma cell (%) 40.2% 55.3% 15.0% 30.5% 18.0% 66.2% 70.3% 21.0%
Chromosome Normal Normal Normal Normal Normal Normal Normal del 13q
Disease status at ASCT CR VGPR PR PR PR PR PR PR
Disease status after ASCT CR CR CR CR CR NA CR CR
Infused CD34+cells/kg of recipient 4.5×10
6 6.0×10
6 9.0×10
6 3.5×10
6 4.7×10
6 3.8×10
6 7.8×10
6 4.8×10
6
ANC >500/μL from ASCT  +D13 +D18 +D10 +D11 +D14 NA +D13 +D19
Platelet ＞20,000/μL from ASCT +D14 +D20 +D10 +D11 +D17 NA +D17 +D20
Relapse after ASCT Yes Yes No No No NA Yes Yes
Current status Alive Alive Alive Alive Alive Death Death Death
Progression-free survival (months) 40.2 8.1 22.5  22.1 15.5 NA 7.4 2.6
Overall survival (months) 59.5 52.8 36.3 26.2 23.1 4.1 30.3 7.1
a)Age and performance status at diagnosis, 
b)Durie-salmon stage, 
c)International staging system stage.
Abbreviations: No, number; ECOG, eastern cooperative oncology group; DS stage, Durie-salmon stage; ISS stage, International staging system 
stage; ANC, absolute neutrophil count; ASCT, autologous stem cell transplantation; NA, not applicable; CR, complete remission; VGPR, very good
partial remission; PR, partial remission.
Table 2. Non-hematologic toxicities.
Non-hematologic toxicities N (%)
Fever 
  Documented pneumonia
  Documented Gram (+) bacteremia
8 (100)
1 (12.5)
1 (12.5)
Mucositis
  All grades
  Grade 3 or 4
4 (50.0)
1 (25.0)
Diarrhea 
  All grades
  Grade 3 or 4
1 (12.5)
0 (0.0)
Peripheral neuropathy
  De novo
  Pre-existing
0 (0.0)
2 (25.0)
Dermographic/allergic reaction 1 (12.5)
DISCUSSION
  Since the introduction of bortezomib for the treatment 
of MM, few reports have addressed the feasibility of using 
a combination of bortezomib plus melphalan as a condition-
ing regimen [13, 14]. A group from the University of Arkansas 
reported an overall response rate of 73% with adequate bone 
marrow recovery: the median time to recovery of the absolute 
neutrophil count (＞1,000/mm
3) and platelet count (＞
50,000/mm
3) was 13 and 17 days, respectively (Hollmig K, 
et al. Blood 2004; Abstract #929). A randomized phase I 
trial of melphalan plus bortezomib as conditioning regimen 
for ASCT also showed a safe profile with engraftment kinetics 
(Lonial S, et al. Blood 2007;110:288a; Abstract #949). 
Recently, the Intergroupe Francophone du Myelome (IFM) 
phase II trial reported that conditioning using bortezo-
mib/melphalan produced almost 70% of CR and VGPR with 
no toxic death [14].
  Although the conditioning regimen, including bortezomib 
was variable in previous studies, our conditioning regimen 
was designed according to the first report using the combina-
tion of bortezomib and melphalan (Hollmig K, et al. Blood 
2004; Abstract #929). Because bortezomib should be ad-
min is t ere d wit h  an  in t er v al o f  72 h o ur s,  b o rt ez o mib  was  
infused on day-4 and -1. To achieve a synergistic effect 
of the 2 drugs, bortezomib was administered on the same 
day as melphalan, similar to the other regimen consisting 
of bortezomib (1.3 mg/m
2) and melphalan (50 mg/m
2) given 
on day -6 and -3 [13]. Thus, we divided the dose of melphalan 
(200 mg/m
2 int o  50 mg /m
2 and 150 mg/m
2) to achieve a Korean J Hematol 2010;45:183-7.
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synergism, while maintaining the intensity of high-dose mel-
phalan (200 mg/m
2).
  Our results indicated that the addition of bortezomib in 
the conditioning regimen dramatically improved CR from 
11% to 35%. Furthermore, the response rate after ASCT 
was not different between the VAD induction group and 
the bortezomib/dexamethasone group. Therefore, it is possi-
ble that a bortezomib-containing conditioning regimen could 
improve the quality of response induced by VAD. Our results 
also showed a high response rate with adequate bone marrow 
recovery and unremarkable non-hematologic toxicities. This 
improvement in the response after ASCT might be related 
to the synergy between bortezomib and melphalan that was 
shown in the previous studies [11, 12].
  The median duration of PFS of all patients was 15.3 months 
and the median PFS of the 6 newly diagnosed patients was 
21.1 months. Although this result might be comparable with 
previous single ASCT studies in newly developed MM pa-
tients [15, 16], the improvement in the degree of response 
following bortezomib plus high-dose melphalan condition-
ing did not translate into an improvement in PFS in this 
study. However, caution should be exercised when interpret-
ing the results of a pilot study that has a small study 
population.
  Although the mechanism of the synergistic effect remains 
to be clarified, several different potential mechanisms of 
bortezomib may be involved, including induction of apopto-
sis, blockade of nuclear factor kappa B (NF-κB), and in-
hibition of cell-cycle progression [17, 18]. Recently, it has 
been reported that the sequence of administration of bortezo-
mib and melphalan could be important when they were 
used as a conditioning regimen (Lonial S, et al. Blood 
2007;110:288a; Abstract #949). Thus, melphalan followed 
by bortezomib may be superior to bortezomib followed by 
melphalan because bortezomib may upregulate the an-
ti-apoptotic protein myeloid cell leukemia 1 (MCL-1) [19]. 
In this study, melphalan was administered before bortezo-
mib, but its efficacy should be confirmed by further studies 
with larger study populations. 
  Although 1 treatment-related death occurred, the addition 
of bortezomib may not have amplified the toxicity of melpha-
lan in the light of adequate overall bone marrow recovery. 
Our case of toxic death might not be associated with bortezo-
mib, because the radiologic findings of our patient were 
different from those of bortezomib-induced lung disease and 
showed typical upper lobar pneumonia [20, 21]. While pe-
ripheral neuropathy may be the main adverse effect of borte-
zomib, there was no de novo case of peripheral neuropathy 
in this study. It should be noted that peripheral neuropathy 
was present at the time of ASCT in 2 patients and did not 
worsen after conditioning. Other non-hematologic toxicities 
associated with the bortezomib-melphalan conditioning reg-
imen were relatively mild and manageable. Only 1 patient 
experienced grade 3 mucositis. Because responders showed 
long-term sustained response after ASCT, this effect could 
be prolonged if an appropriate maintenance therapy could 
be used after bortezomib-melphalan conditioning following 
ASCT. 
  In conclusion, this is the first report on the efficacy of 
bortezomib plus high-dose melphalan therapy in Asian pa-
tients with MM. We believe that this conditioning regimen 
may be more effective for ASCT than melphalan alone. 
However, the feasibility of this conditioning regimen should 
be further evaluated in a larger study population. 
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